Less than a tenth of people eligible to benefit from obesity jabs including Wegovy are able to get them, caution the WHO as it publishes its inaugural recommendations on the drugs.
With in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for increased and just access to these injectable treatments.
According to estimates, more than two billion could be living with obesity by 2030 if no action is taken.
"The latest guidance acknowledges that excess weight is a long-term condition that can be managed with holistic and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are major barriers to broad access to the jabs that can aid individuals in losing considerable weight, notes the body.
Weight-Loss Drug Shortage
Despite the current most favorable case, the manufacturing of such drugs could only cover about 100 million people – less than 10% of the global need, per the WHO.
The guideline encourages countries and companies to increase access, through approaches such as voluntary licensing.
The intellectual property rights on semaglutide – the primary component of a leading brand – is scheduled to end in multiple nations in 2026.
The Way Weight-Loss Injections Work
The injections replicate a natural hormone to slow digestion, curb appetite and increase satiety so people reduce food intake.
Individuals usually start to lose weight within a few weeks of beginning the regular doses.
Studies indicates patients may regain a significant portion a year later of stopping the medication, when their typical appetite come back.
Being carrying excess weight raises your likelihood for contracting health problems, such as type 2 diabetes, heart disease, brain attack, and certain cancers.
Excess weight impacts individuals in all nations and was linked to 3.7 million fatalities worldwide in 2024, as per the WHO.
